Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LJPC-501 in Pediatric Hypotension
NCT03431077Phase 2Completed
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Feb 2018
- Primary completion
- Apr 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Angiotensin II in Catecholamine-resistant hypotension, Distributive shock (DS), sponsored by La Jolla Pharmaceutical Company. Started Feb 2018; status: completed.
02
Drugs
Angiotensin II
03
Conditions
Catecholamine-resistant hypotensionDistributive shock (DS)
Beyond the preview
Go deeper on NCT03431077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431077.